查了下资料：
Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer
Published on April 1, 2011 at 12:02 AM · No Comments
inShare.02Share0diggsdiggAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has completed enrollment in its ALN-VSP Phase I multi-center, multinational, open label, dose escalation clinical trial. The study's objectives were to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors with liver involvement. ALN-VSP was administered to over 40 patients at doses ranging from 0.1 to 1.5 mg/kg, with multiple patients continuing to receive therapy on the study. Alnylam will present data from its ALN-VSP program at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 - 7, 2011.
"We are pleased to have completed enrollment in our Phase I trial with ALN-VSP," said Jared Gollob, M.D., Senior Director, Clinical Research at Alnylam. "The data from this program have been encouraging to date, and the results are important not only for the continued advancement of ALN-VSP toward Phase II studies but also for the overall advancement of systemically delivered RNAi therapeutics. We will be presenting updated data from this Phase I trial at the ASCO Annual Meeting in June."
"Both primary liver cancer and metastatic disease of the liver are associated with poor prognosis for patients, and new therapies are clearly needed," said Josep Tabernero, M.D., Chairman of the Medical Oncology Department and Phase I Program at Vall d'Hebron University Hospital in Barcelona, Spain. "This study represents an important step in the development of a novel therapeutic strategy to treat this devastating disease, and we look forward to evaluating the full data from this trial."
Alnylam公司完成在AlN到距VSP第一阶段试验对肝癌患者报名
Published on April 1, 2011 at 12:02 AM · No Comments
inShare.00Share0diggsdiggAlnylam制药公司（Nasdaq：ALNY）是一家领先的RNAi疗法公司，今天宣布，它已经完成了它的AlN到距VSP阶段入学我多中心，跨国公司，开放标签，剂量递增临床试验。这项研究的目的是评估与肝硬化晚期实体肿瘤患者参与的安全性，耐受性，药代动力学和药效学。 AlN到距VSP是管理超过40位病人从0.1到1.5毫克/公斤，继续接受治疗多发性骨髓瘤患者的研究。 Alnylam公司将展示其AlN到距VSP在美国临床肿瘤学会（ASCO）年6月3日举行会议程序数据 - 7，2011。
“我们很高兴能够完成我们的第一期上以AlN -距VSP试报名，说：”贾里德Gollob，医学博士，高级总监，临床研究在Alnylam公司。 “从这个方案的数据已经令人鼓舞的日期，其结果不仅对氮化铝，距VSP对II期临床试验的持续提高，而且对系统性RNAi疗法的全面发展提供重要的。我们将展示最新数据该阶段我在美国临床肿瘤学会年会在六月的审判。“
“无论是原发性肝癌和转移性的肝脏疾病都与病人的预后较差，显然需要新的疗法，说：”Josep Tabernero医师，医学肿瘤学系系主任一期工程于瓦尔德Hebron大学医院计划在巴塞罗那，西班牙。 “这项研究代表了一个新的治疗策略，以治疗这种破坏性疾病发展的重要一步，我们期待着评估这个试验的全部数据。”
看来还得待以时日。。。
